+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data



Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data



Infection and Drug Resistance 12: 553-570



Tafenoquine is an 8-aminoquinoline with activity against all human life cycle stages of Plasmodium vivax, including dormant liver stages - so called hypnozoites. Its long half-life of ~15 days is allowing for a single exposure regimen. It has been under development since 1980 and received approval by the US Food and Drug Administration in summer 2018 as an anti-relapse drug for P. vivax malaria in patients aged 16 years and older and for prophylaxis of malaria caused by any Plasmodium species in adults. Prior to tafenoquine administration, glucose-6-phosphate dehydrogenase (G6PD) deficiency needs to be excluded by testing. Individuals with a deficient G6PD activity are at risk of tafenoquine-induced hemolysis - as is the case for primaquine, the mainstay drug for P. vivax radical cure. A wealth of clinical studies have been conducted and are still ongoing to assess the safety, tolerability, and efficacy of tafenoquine. This review focuses on data emerging from the latest clinical trials on P. vivax radical cure with tafenoquine, the key studies for regulatory approval of tafenoquine, and elucidates the latest hypothesis on the mode of action.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066598365

Download citation: RISBibTeXText

PMID: 30881061

DOI: 10.2147/idr.s151031


Related references

Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Design Development and Therapy 10: 2387-2399, 2016

Randomized Dose-Ranging Study of the Safety and Efficacy of Wr 238605 (Tafenoquine) in the Prevention of Relapse of Plasmodium vivax Malaria in Thailand. The Journal of Infectious Diseases 180(4): 1282-1287, 1999

Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. Journal of Infectious Diseases 180(4): 1282-1287, 1999

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malaria Journal 15: 97, 2016

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383(9922): 1049-1058, 2014

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clinical Infectious Diseases 39(8): 1095-1103, 2004

Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database of Systematic Reviews 2015(4): Cd010458, 2015

Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine 380(3): 215-228, 2019

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine 380(3): 229-241, 2019

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine 380(19): 1875, 2019

Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. International Ophthalmology 39(8): 1767-1782, 2019

A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria. Plos one 12(11): E0187376, 2017

Tafenoquine for the treatment of recurrent Plasmodium vivax malaria. American Journal of Tropical Medicine and Hygiene 76(3): 494-496, 2007

Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax Malaria. Antimicrobial Agents and ChemoTherapy 59(10): 6188-6194, 2015

Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria. Journal of Infectious Diseases 190(8): 1456-1463, 2004